Advertisement

Tumor Biology

, Volume 35, Issue 8, pp 7555–7560 | Cite as

Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies

  • Yan Zhao
  • Xiaoer Yang
  • Xiaojiao Hao
  • Xiaolin Pan
  • Bo Zhao
  • Jingwen Ma
  • Jian Fang
  • Minghong Zhao
Research Article

Abstract

Due to its important biological function as a key negative regulator of p53, the mouse double minute 2 homologue (MDM2) gene has been extensively studied. A functional variant in the MDM2 gene promoter, single-nucleotide polymorphism 309 (SNP309) T > G (rs2279744), has been reported to cause an increase in MDM2 protein levels and impairment of p53 tumor suppressor activity, which may be associated with the development of cancer. A number of studies were performed to investigate the relationship between this SNP and endometrial cancer. But, the results remain controversial. Thus, we performed a comprehensive meta-analysis to derive a more precise estimation of this susceptibility. There were seven eligible articles with a total of 1,278 patients and 2,189 controls included in the meta-analysis. In the present study, we found significant associations under the allele contrast and recessive model. The G allele was associated with elevated risk for endometrial cancer [allele contrast OR = 1.33, 95 % confidence interval (CI) = 1.12–1.58, P(Z) = 0.0009, P(Q) = 0.02)], while the homozygous GG genotype may also increase the risk of endometrial cancer [OR = 1.88, 95 % CI = 1.40–2.52, P(Z) < 0.0001, P(Q) = 0.02]. In the subgroup analysis by ethnicity, we found similar significant results for both Caucasians [allele contrast OR = 1.41, 95 % CI = 1.04–1.92, P(Z) = 0.03, P(Q) = 0.001; recessive model OR = 1.89, 95 % CI = 1.10–3.23, P(Z) = 0.02, P(Q) = 0.002] and Asians [allele contrast OR = 1.24, 95 % CI = 1.01–1.53, P(Z) = 0.04, P(Q) = 0.86; recessive model OR = 1.75, 95 % CI = 1.24–2.45, P(Z) = 0.001, P(Q) = 0.75]. Overall, the meta-analysis demonstrated that the MDM2 SNP309 polymorphism may be associated with increased risk of endometrial cancer.

Keywords

MDM2 SNP309 (T > G) rs2279744 Single-nucleotide polymorphism (SNP) Variant Endometrial cancer 

Notes

Conflicts of interest

None

Supplementary material

13277_2014_1886_Fig4_ESM.jpg (22 kb)
Fig. S1

Funnel plot for the association of the MDM2 SNP309 with endometrial cancer risk (allele contrast). (JPEG 22 kb)

13277_2014_1886_MOESM1_ESM.tif (843 kb)
High resolution image (TIFF 843 kb)
13277_2014_1886_Fig5_ESM.jpg (22 kb)
Fig. S2

Funnel plot for the association of the MDM2 SNP309 with endometrial cancer risk (recessive model). (JPEG 21 kb)

13277_2014_1886_MOESM2_ESM.tif (926 kb)
High resolution image (TIFF 925 kb)
13277_2014_1886_Fig6_ESM.jpg (21 kb)
Fig. S3

Funnel plot for the association of the MDM2 SNP309 with endometrial cancer risk (dominant model). (JPEG 21 kb)

13277_2014_1886_MOESM3_ESM.tif (840 kb)
High resolution image (TIFF 839 kb)

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS. 2002;110(10):673–89.PubMedCrossRefGoogle Scholar
  3. 3.
    Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129(2):415–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303.PubMedCrossRefGoogle Scholar
  5. 5.
    Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res. 2007;67(12):5831–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Soslow RA, Shen PU, Chung MH, Isacson C. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol. 1998;17(2):129–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology. 1998;33(5):440–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.PubMedCrossRefGoogle Scholar
  9. 9.
    Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007;104(3):660–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(4):983–6.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMedGoogle Scholar
  12. 12.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRefGoogle Scholar
  13. 13.
    Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol. 2009;113(1):109–14.PubMedCrossRefGoogle Scholar
  14. 14.
    Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009;22(4):101–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22(2):49–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, et al. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep. 2013;30(1):25–34.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Zajac A, Stachowiak G, Pertynski T, Romanowicz H, Wilczynski J, Smolarz B. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Pol J Pathol. 2012;63(4):278–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res. 2003;1(14):1009–16.PubMedGoogle Scholar
  19. 19.
    Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420(1):25–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer. Growth Factors. 2005;23(3):183–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res. 1995;1(1):71–80.PubMedGoogle Scholar
  23. 23.
    Sheikh MS, Shao Z-M, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res. 1993;53(14):3226–8.PubMedGoogle Scholar
  24. 24.
    Kato K, Horiuchi S, Takahashi A, Ueoka Y, Arima T, Matsuda T, et al. Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway. J Biol Chem. 2002;277(13):11217–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell. 2000;103(2):321–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Kato K, Ueoka Y, Hachiya T, Nishida J, Wake N. Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Oncogene. 1997;15(25):3037–46.PubMedCrossRefGoogle Scholar
  27. 27.
    Suga S, Kato K, Ohgami T, Yamayoshi A, Adachi S, Asanoma K, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 2007;105(2):341–50.PubMedCrossRefGoogle Scholar
  28. 28.
    Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006;66(10):5104–10.PubMedCrossRefGoogle Scholar
  29. 29.
    Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006;43(6):531–3.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2–SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98(4):285–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2717–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O'Mara T, et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet. 2011;43(5):451–4.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Long J, Zheng W, Xiang YB, Lose F, Thompson D, Tomlinson I, et al. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(6):980–7.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    De Vivo I, Prescott J, Setiawan VW, Olson SH, Wentzensen N, Australian National Endometrial Cancer Study Group, et al. Genome-wide association study of endometrial cancer in E2C2. Hum Genet. 2014;133(2):211–24.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yan Zhao
    • 1
  • Xiaoer Yang
    • 2
  • Xiaojiao Hao
    • 1
  • Xiaolin Pan
    • 1
  • Bo Zhao
    • 1
  • Jingwen Ma
    • 1
  • Jian Fang
    • 1
  • Minghong Zhao
    • 1
  1. 1.Department of Gynecology and ObstetricsBaoshan Hospital of Integrated Traditional Chinese and Western MedicineShanghaiPeople’s Republic of China
  2. 2.Department of Clinical LaboratoryShanghai Changning Maternity Infant Health HospitalShanghaiPeople’s Republic of China

Personalised recommendations